Bio-Bridge Science, Inc. Announces the Appointment of Two New Members to the Board of Directors.

OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB: BGES) a developer of vaccines with broad preventative and therapeutic applications, is pleased to announce that Mr. Trevor Roy and Mr. Anthony Cheung have been named to the Company's board of directors.

Both Mr. Roy and Mr. Cheung bring to Bio-Bridge abundant successful business experience and numerous international relationships. Their addition to the board of directors will help Bio-Bridge quickly reach strategic goals in the pursuit to develop vaccines to treat and improve human health.

"On behalf of Bio-Bridge Science, we welcome Mr. Roy and Mr. Cheung to the board of directors. I am confident that they will contribute greatly to our goal to become a leading international vaccine development and production company," said Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science, Inc.

Mr. Roy was a graduate of the University of Sydney. His initial career was in education where he was a teacher and administrator at both high school and tertiary levels. Then in a business career spanning 30 years, Mr. Roy, with his investment and management experience, both in his home country of Australia and internationally, has been in a wide range of industries including rural/agricultural, theatrical, marketing and promotions, food manufacturing and distribution, medical, and telephony and communications. For the past 18 years, Mr. Roy has been CEO (now Chairman) of the Creata Group of Companies and has been instrumental in establishing its business as a global provider of marketing and promotional programs in 18 offices throughout 12 countries.

Mr. Cheung's early career was in finance, accounting and auditing with John B. P. Byrne & Co., now Grant Thornton in Hong Kong. This formed the foundation of a successful business management and investment career over 25 years that now includes: ownership of manufacturing facilities in Hong Kong and China (Dongguan) with an excess of 10,000 employees producing over 200 million consumer products annually; ownership of a Class 2 hospital in China (Fujian); and (commercial) real estate investments and developments in Hong Kong, China and the United States.

Forward Looking Statements:

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information.